# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chemotherapy Delivered Via TAMP With Prior Chemoradiation Shows 27-Month Overall Survival; Ongoing Phase III Trial Evaluates Ta...
Ascendiant Capital analyst Edward Woo initiates coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and announces Price Tar...
Dear Fellow RenovoRx Shareholders,The first quarter of 2024 marked a significant period in our company's evolution, and we ...
Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery w...